Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage
Neurizon Therapeutics, a Melbourne biotech developing an ALS treatment, has appointed industry veteran Dr Chris Bremer as CEO as its lead drug NUZ-001 heads toward Phase 2/3 trial results in 2027.